Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Author(s): Ross A. Soo, MBBS, PhD¹; Byoung Chul Cho, MD, PhD²; Joo-Hang Kim, MD³; Myung-Ju Ahn, MD, PhD⁴; Ki Hyeong Lee, MD⁵; Anastasia Zimina, MD⁶; Sergey Orlov, MD⁷; Igor Bondarenko, MD, PhD⁸; Yun-Gyoo Lee, MD⁹; Yueh Ni Lim, MD¹⁰; Sung Sook Lee, MD¹¹; Kyung-Hee Lee, MD, PhD¹²; Yong Kek Pang, MD¹³; Chin Heng Fong, MD¹⁴; Jin Hyoung Kang, MD¹⁵; Chun Sen Lim, MD¹⁶; Pongwut Danchaivijitr, MD¹⁷; Saadettin Kilickap, MD¹⁸; James Chih-Hsin Yang, MD, PhD¹⁹; Cagatay Arslan, MD²⁰; Hana Lee, MS²¹; Seong Nam Park, MPH²¹; Irfan Cicin, MD²²

Source: https://doi.org/10.1016/j.jtho.2023.08.017

Dr. Maen Hussein's Thoughts

Lazertinib, third generation EGFR inhibitor, has good activity in patients with brain mets promising…

INTRODUCTION

Lazertinib, a third-generation mutant-selective EGFR tyrosine kinase inhibitor, improved progression-free survival compared with gefitinib in the phase 3 LASER301 study (ClinicalTrials.gov Identifier: NCT04248829). Here, we report the efficacy of lazertinib and gefitinib in patients with baseline central nervous system (CNS) metastases.

METHODS

Treatment-naive patients with EGFR–mutated advanced NSCLC were randomized one-to-one to lazertinib (240 mg/d) or gefitinib (250 mg/d). Patients with asymptomatic or stable CNS metastases were included if any planned radiation, surgery, or steroids were completed more than 2 weeks before randomization. For patients with CNS metastases confirmed at screening or subsequently suspected, CNS imaging was performed every 6 weeks for 18 months, then every 12 weeks. End points assessed by blinded independent central review and Response Evaluation Criteria in Solid Tumors version 1.1 included intracranial progression-free survival, intracranial objective response rate, and intracranial duration of response.

RESULTS

Of the 393 patients enrolled in LASER301, 86 (lazertinib, n = 45; gefitinib, n = 41) had measurable and or non-measurable baseline CNS metastases. The median intracranial progression-free survival in the lazertinib group was 28.2 months (95% confidence interval [CI]: 14.8–28.2) versus 8.4 months (95% CI: 6.7–not reached [NR]) in the gefitinib group (hazard ratio = 0.42, 95% CI: 0.20–0.89, p = 0.02). Among patients with measurable CNS lesions, the intracranial objective response rate was numerically higher with lazertinib (94%; n = 17) versus gefitinib (73%; n = 11, p = 0.124). The median intracranial duration of response with lazertinib was NR (8.3–NR) versus 6.3 months (2.8–NR) with gefitinib. Tolerability was similar to the overall LASER301 population.

CONCLUSIONS

In patients with CNS metastases, lazertinib significantly improved intracranial progression-free survival compared with gefitinib, with more durable responses.

Author Affiliations

¹Department of Haematology-Oncology, National University Cancer Institute, Singapore; ²Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; ³CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; ⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ⁵Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea; ⁶State Budgetary Healthcare Institution of Omsk Region, Omsk, Russia; ⁷Pavlov State Medical University, Ulitsa L’va Tolstogo, St. Petersburg, Russia; ⁸Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine; ⁹Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ¹⁰Hospital Umum Sarawak, Jalan Hospital, Kuching, Malaysia; ¹¹Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea; ¹²Division of Hematology/Oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea; ¹³University Malaya Medical Centre, University of Malaya, Petaling Jaya, Malaysia; ¹⁴Hospital Pulau Pinang, Pulau Pinang, Malaysia; ¹⁵Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; ¹⁶Oncology Department, Hospital Sultan Ismail, Jalan Mutiara Emas Utama, Johor, Malaysia; ¹⁷Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ¹⁸Department of Medical Oncology, İstinye University Faculty of Medicine, Liv Hospital Ankara, Ankara, Turkey; ¹⁹National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan; ²⁰Department of Medical Oncology, Izmir University of Economics Medical Point Hospital, İzmir, Turkey; ²¹Yuhan Corporation, Seoul, Republic of Korea; ²²Department of Medical Oncology, Trakya University Medical Center, Edirne, Turkey

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Progression-free survival (PFS) was higher in the Sun group vs chemotherapy, 10.3 m vs 7.5 m with HR of .65 with higher responses (58.9% vs 31.1%) diarrhea high CK and anemia were the most common side effects. The issue is that amivan was not part of treatment and compared to chemotherapy ami in addition to chemotherapy had 11m PFS also in this trial few had brain mets so no evaluation for CNS protection or treatment. But an oral agent in patients who don’t want to come to the office often.

Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

109 patients with stage II or IIIA disease, 2-year investigator-assessed event-free survival was 92% with selpercatinib and 61% with placebo (HR for disease recurrence, progression, or death, 0.17 P<0.001). Patients with stage IB, II, or IIIA non–small-cell lung cancer (NSCLC), event-free survival at 2 years was 94% with selpercatinib and 70% with placebo. Genomic testing is expanding now for early stage NSCLC. More study in the adjuvant setting showing promise with targeted therapy.

Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

It seems the old cliche of more drugs than patients is becoming true for most providers here. The data needs to mature further here but likely this will be another option for Anaplastic lymphoma kinase (ALK)+ non–small-cell lung cancer (NSCLC) patients in the adjuvant setting. It does look like CNS protection benefits are meaningful as well.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

The median overall survival (OS) was 27·9 months with ivonescimab versus 23·7 months with tis.

Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial

Median progression-free survival was significantly longer with sac-TMT plus pembrolizumab than with pembrolizumab alone (not reached vs 5·7 m) this is regardless of PDL-1 expression (1-49 or >50).